We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Profile Predicts Risk of Bladder Cancer Recurrence

By LabMedica International staff writers
Posted on 07 Apr 2014
A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status.

Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment. To identify genetic variants that modify bladder cancer prognosis, investigators at Dartmouth Medical School (Lebanon, NH, USA) focused on genes involved in major biological carcinogenesis processes (apoptosis, proliferation, DNA repair, hormone regulation, immune surveillance, and cellular metabolism).

The investigators analyzed genes from 563 bladder cancer patients to identify genetic variants that modify time to bladder cancer recurrence and patient survival. Patients were followed for a median of 5.4 years during which about half of them experienced at least one recurrence.

Results revealed that those patients with variants in the ALDH2 (aldehyde dehydrogenase 2) gene, which encodes an enzyme involved in alcohol metabolism, were likely to experience bladder cancer recurrence shortly after treatment. Time to recurrence was also shorter for patients who had a variant in the VCAM1 (vascular cellular adhesion molecule 1) gene, which encodes a glycoprotein involved in the development of lymphoid tissues, and were treated with immunotherapy. Patients who had noninvasive tumors and a variant in the DNA repair gene XRCC4 tended to live longer than patients who did not have the variant.

“The genetic markers that we found could potentially be useful for individually tailoring surveillance and treatment of bladder cancer patients,” said first author Dr. Angeline S. Andrew, assistant professor of community and family medicine at Dartmouth Medical School.

The study that identified biomarkers linked to bladder cancer recurrence was published in the March 26, 2014, online edition of the journal BJU International.

Related Links:

Dartmouth Medical School



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Latest Pathology News

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis